Baotou Dongbao Bio-Tech Co., Ltd. Class A

Baotou Dongbao Bio-Tech Co., Ltd. Class A

SSZSE:300239
4.73
CNY
-0.05
(-1.05%)
0.10EPS
52.56P/E
3.24BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.97
0.63
0.72
0.69
0.77
0.98
0.97
0.86
1.09
1.59
1.64
1.49
1.27
1.43
Basic EPS, GAAP
0.11
0.01
0.01
0.04
0.05
0.07
0.06
0.04
0.06
0.18
0.2
0.14
0.09
0.1
Free Cash Flow per Basic Share
-0.04
-0.07
-0.1
-0.25
-0.23
0.01
-0.34
-0.17
- -
0.15
0.11
-0.01
0.05
- -
Dividend per Share
0.04
0.04
0.04
0.01
0.02
0.03
0.04
0.04
0.01
0.02
0.04
0.03
0.03
0.02
Book Value per Share
0.89
0.86
1.53
1.56
1.58
1.62
1.89
1.9
2.4
2.57
2.79
2.93
2.9
2.98
Tangible Book Value per Share
0.86
0.82
1.38
1.4
1.42
1.47
1.77
1.74
2.09
2.32
2.54
2.69
2.67
2.76
Basic Weighted Avg Shares
395
396
406
461
461
461
507
523
564
593
593
594
586
586
Sales/Revenue/Turnover
382
251
292
317
356
453
492
449
612
943
975
885
745
835
Operating Margin (%)
14.06
4.42
4.11
4.55
7.99
9.69
7.52
5.97
7.33
14.42
15.38
12.16
10.72
10.21
Depreciation Expense
13
15
16
18
27
36
35
49
55
86
82
86
97
- -
Net Income, GAAP
43
5
6
19
22
34
33
18
36
109
120
86
54
61
Effective Tax Rate (%)
16.75
24.7
20.26
15.65
15.2
13.26
9.87
7.47
13.76
12.31
11.85
13.6
12.25
8.85
Profit Margin (%)
11.16
1.95
2.02
6.07
6.29
7.5
6.69
4.11
5.96
11.6
12.3
9.72
7.29
7.28
Working Capital
250
133
420
243
121
116
228
133
471
708
1,049
911
913
844
LT Debt
108
10
10
10
24
16
27
8
- -
152
463
472
494
465
Total Equity
351
341
707
719
730
751
990
998
1,604
1,756
1,893
1,739
1,723
1,771
Return on Invested Capital (%)
8.11
0.61
0.51
2.11
3.04
4.33
3.48
1.69
2.6
6.33
5.87
4.01
2.36
2.62
Return on Capital (%)
11.43
2.7
2.11
2.66
3.04
4.64
3.66
2.22
2.98
6.11
5.42
3.62
2.6
3.02
Return on Common Equity (%)
12.63
1.41
1.12
2.7
3.09
4.59
3.78
1.86
3.02
7.42
7.52
5.06
3.14
3.5

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
8
9
1
LT Borrowings
498
500
465
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
594
594
594
Market Capitalization
3,241
3,164
3,241

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,134
1,156
1,117
Cash, Cash Equivalents & STI
459
453
361
Accounts Receivable, Net
179
207
202
Inventories
416
398
432
Total Current Liabilities
236
274
274
Payables & Accruals
- -
- -
- -
ST Debt
8
9
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.77%
13.78%
-0.93%
Free Cash Flow
5,342%
11,417.07%
-431.67%
Net Income, GAAP
48.97%
48.43%
-36.8%
Sales/Revenue/Turnover
11.68%
13.77%
-15.78%
Total Cash Common Dividend
23.68%
20.64%
15.62%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
242
202
189
252
885
2025
188
181
- -
213
745
2026
191
224
208
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.04
0.03
0.03
0.14
2025
0.03
0.03
- -
0.01
0.09
2026
0.03
0.03
0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.02
- -
- -
0.03
2025
- -
0.03
- -
- -
0.03
2026
- -
0.01
0.01
- -
- -

Company Description

CEO
Fang Liu
Full Time Employees
1,681
Sector
Process industries
Industry
Chemicals: specialty
Address
No. 46 Huanghe Street Baotou MO China 014030
IPO Date
Jun 24, 2011
Business
Baotou Dongbao Bio-Tech Co., Ltd. Baotou Dongbao Bio-Tech Co., Ltd. (300239.SZ), founded in 1997 as the successor to Baotou Fine Gelatin Factory established in the 1960s, develops, manufactures and sells gelatin, collagen and related derivative products from its headquarters in Baotou, Inner Mongolia, China. The company operates three production bases with annual capacities of 13,500 metric tons for gelatin and 4,300 metric tons for collagen peptides; its core offerings include pharmaceutical gelatin for empty hard capsules, softgels and plasma substitutes; food additive gelatin serving as thickener, stabilizer, emulsifier in confectionery, dairy, meat and yogurt products; photographic gelatin; hydrolyzed collagen powder and granules; collagen peptide powder, granules and agglomerated forms; fish collagen peptide; private label collagen OEM/ODM services; feed-grade calcium hydrogen phosphate; and bio-organic fertilizers such as organic, water-soluble and compound microbial variants. Products target pharmaceutical, food and nutraceutical, industrial, fertilizer and animal feed sectors primarily in China with international exports, holding top production rankings and high market share in China's softgel and hard capsule segments. In 2024, Baotou Dongbao Bio-Tech Co., Ltd. completed its acquisition of the remaining 40% stake in Qingdao Yiqing Biotechnology Co., Ltd. for CNY 230 million, achieving 100% ownership to bolster collagen production capabilities.